Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-90 years ;~2. COVID-19 confirmed case ;~3. Cases showing respiratory symptoms, checking at least one of the following criteria:~   1. Cough, dyspnea, respiratory rate \> 24 breaths/min~  2. Oxygen saturation \< 95% at rest in ambient air~  3. PaO2 \< 70mmHg~  4. Scanographic pulmonary compatible with COVID in the absence of any other etiology~4. Risk of deterioration, checking at least one of the following comorbidity criteria :~   1. Chronic respiratory pathology~  2. Diabetes~  3. Cancer pathology~  4. Cardiovascular disease~  5. Chronic kidney failure~  6. Congenital or acquired immunodeficiency~  7. Cirrhosis at stage B~  8. Major sickle cell syndrome~  9. BMI \> 30 kg/m2~OR one of the biological criteria :~1. D-dimer 1 µg/mL,~2. Lymphocytes \< 0.8 G/L,~3. Ferritin \> 300 µg/L,~4. Troponin I \> 11 pg/mL or Troponin T \> 24.8 pg/mL~Exclusion Criteria:~* Patients admitted in intensive care within the first 6 hours of hospital care,~* Patients after 10 days from the start of symptoms~* Age \< 18 years and \> 90 years~* Long-term oxygen-dependent patients (at home),~* Decompensated chronic cardiac, respiratory, urological pathology~* Patient refusing administration of blood products,~* Allergic reaction to plasma products,~* IgA deficiency,~* Contraindication to transfusion~* Ig transfusion within 30 days,~* Patient currently participating to another clinical trial,~* Pregnant women,~* No affiliated to the social security,~* Person deprived of liberty by a legal or administrative decision, person under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SARS-CoV-2 patients treated with convalescent plasma (Type: EXPERIMENTAL): Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
- SARS-CoV-2 patients treated with standard plasma (Type: ACTIVE_COMPARATOR): Subjects will receive an intravenous injection of standard Plasma.

Based on this trial design, predict the completion outcome and termination type (if applicable).